Ever since the discovery of antibiotics, microbiologists have worried about and studied how bacteria acquire resistance to these drugs. Adding to the complexity of this problem is the fact that it is not always clear whether the conditions that drive the evolution of resistance in the lab occur in patients suffering from bacterial infections.

This is where the work of Nathalie Balaban -- Professor at the Hebrew University, and our guest on this episode -- comes in. The article we discuss is based on a foundation of research done in her laboratory, but this study makes the important step into the clinic by using samples from a patient with a life-threatening bacterial (MRSA) infection. By analyzing these patient samples, Dr. Balaban and her team were able to understand the conditions that lead to multi-drug resistance in a hospital setting. The work reveals how the ability of bacteria to enter a state of dormancy, also known as tolerance, can act as a stepping stone to resistance and can interfere with the efficacy of drug combinations. Our conversation covers what tolerance is, the conditions that promote tolerance, how it can lead to resistance and impact drug combination therapies, and lastly, integrating this new understanding into clinical microbiology protocols.

"Effect of tolerance on the evolution of antibiotic resistance under drug combinations" in Science (January 2020) by Jiafeng Liu, Orit Gefen, Irine Ronin, Maskit Bar-Meir, Nathalie Q. Balaban.

a16z bio Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature -- what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.

Stay Updated:

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Podcast on Spotify

Listen to the a16z Podcast on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.